Compare ENS & LQDA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ENS | LQDA |
|---|---|---|
| Founded | 1991 | 2004 |
| Country | United States | United States |
| Employees | 9200 | N/A |
| Industry | Industrial Machinery/Components | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.8B | 5.5B |
| IPO Year | 2004 | 2020 |
| Metric | ENS | LQDA |
|---|---|---|
| Price | $189.59 | $27.99 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 5 | 8 |
| Target Price | ★ $252.58 | $107.75 |
| AVG Volume (30 Days) | 383.0K | ★ 950.7K |
| Earning Date | 11-04-2026 | 11-02-2026 |
| Dividend Yield | ★ 0.63% | N/A |
| EPS Growth | N/A | ★ 51.81 |
| EPS | ★ 3.09 | 1.26 |
| Revenue | ★ $216,125,000.00 | $158,320,000.00 |
| Revenue This Year | $3.87 | $366.74 |
| Revenue Next Year | $4.87 | $65.90 |
| P/E Ratio | $59.24 | ★ $56.05 |
| Revenue Growth | 15.85 | ★ 1031.18 |
| 52 Week Low | $108.88 | $21.91 |
| 52 Week High | $244.30 | $93.61 |
| Indicator | ENS | LQDA |
|---|---|---|
| Relative Strength Index (RSI) | 50.41 | 18.20 |
| Support Level | $175.64 | N/A |
| Resistance Level | $182.19 | $39.26 |
| Average True Range (ATR) | 3.81 | 3.29 |
| MACD | 1.34 | -2.08 |
| Stochastic Oscillator | 79.79 | 5.95 |
EnerSys provides stored energy solutions for industrial applications. It also manufactures and distributes energy systems solutions and motive power batteries, specialty batteries, battery chargers, power equipment, battery accessories, and outdoor equipment enclosure solutions to customers. Energy Systems that combine enclosures, power conversion, power distribution, and energy storage are used in the telecommunication and broadband, utility industries, uninterruptible power supplies, and numerous applications requiring stored energy solutions. Its segments include Energy Systems, Motive Power, New Ventures, and Specialty.
Liquidia Corp is a United States-based biopharmaceutical company focused on the development, manufacturing, and commercialization of products that address unmet patient needs, with the current focus directed towards the treatment of pulmonary hypertension (PH) and pulmonary hypertension associated with interstitial lung disease. It conducts research, development, and manufacturing of novel products by applying its proprietary PRINT technology, a particle engineering platform, to enable the precise production of uniform drug particles. Its product includes YUTREPIA (treprostinil) inhalation powder, for the treatment of pulmonary arterial hypertension. The company also conducting studies on L606, an investigational, liposomal formulation of treprostinil.